

Prostate Cancer Metastatic Prostate Cancer

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

Trial Status

Active, not recruiting

Trial Runs In

26 Countries

Trial Identifier

NCT03072238 CO39303

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Hoffmann-La Roche

Sponsor

Phase 3

Phase

NCT03072238 CO39303

Trial Identifiers

Eligibility Criteria:

Gender

Male

Age

>= 18 Years

Healthy Volunteers

No